– Our Platform
An innovative, targeted approach to treating cancer
Our treatment specifically targets unique features of cancer cells, including externalized phosphatidylserine and tumor cell lysosomes by utilizing a small lysosomal protein known as Saposin C.
– Our Pipeline
A Pipeline-in-a-Product asset with potential for multiple indications
BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.
– clinical trials
PHASE 1 Studies Now in Progress
Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Resources
Resources
News
Bexion Pharmaceuticals, Inc. To Present Clinical Data at 2019 NORD Annual Meeting
Clinical results support strong safety and tolerability for BXQ-350. Topline results support progression into Phase II studies. FOR IMMEDIATE RELEASE Covington, KY ~ 4 September 2019 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature a clinical poster presentation at the National Organization for ... Read More
Bexion Pharmaceuticals president and CEO Ray Takigiku Interviewed by Cincinnati Public Radio
Bexion Pharmaceuticals president and CEO Ray Takigiku was interviewed by Cincinnati Public Radio on May 22, 2019. Click here to read more and listen to the interview.